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Cryptococcal infections over a 15 year period at a 
tertiary facility & impact of guideline management
BACKGROUND
Cryptococcosis is an invasive fungal infection caused primarily by Cryptococcus neoformans and 
C. gattii species, associated predominantly with meningoencephalitis and more commonly diagnosed 
in the immunocompromised host 1,2. Discovery of the organism is attributed to Busse in 1894, however 
C. neoformans rose to infamy during the height of the HIV pandemic at a staggering incidence of 3.2% in 
sub-Saharan Africa 1,3. In recent years C. gattii has gained in prominence due to a sustained outbreak in 
British Columbia, Canada 4. 
Incidence, diagnosis and management of cryptococcal infection has altered over time. Improved 
antiretroviral therapy has decreased the incidence of infection in the human immunodeficiency virus (HIV) 
cohort 5. Access to cheap and accurate serological testing and screening of at risk populations has been 
found to be cost-effective 6. Management has changed with the advent of liposomal and lipid complex 
amphotericin B as well as the most recent 2010 Infectious Diseases Society of America (IDSA) treatment 
guidelines 7. 
At our facility we have seen a trend towards increased incidence amongst our renal transplant cohort 8. 
Analysis of this cohort revealed a much lower mortality rate compared with international data. Given this 
information we aimed to assess all cryptococcal infections managed at our facility from 2001-2015 in order 
to determine potential increase in incidence, clinical and biochemical presentation, and comparison of 
outcomes prior to and after introduction of the 2010 IDSA guidelines.
METHODS
All potential cases of Cryptococcus infection were identified via the Queensland Health pathology service 
database AUSLAB, using search criteria for a positive cryptococcal antigen titre and or positive Cryptococcus 
microbiology culture results. A definitive case was a positive culture from tissue, blood, CSF or positive CSF 
cryptococcal antigen. Probable was defined as a positive serological cryptococcal titre. Statistical analysis 
was conducted using IBM SPSS Statistics Version 23.0 and Microsoft Excel.
RESULTS
Figure 1. Number of cases per year diagnosed and managed at our facility
102 potential cases were identified using the aforementioned methodology. 5 patients were not managed 
at our facility and were excluded from analysis. There appears to be a rise in incidence however this was 
not statistically significant in the transplant cohort and could not be accurately calculated at population 
level, Figure 1 8. Cryptococcal meningitis was the most common presentation of cryptococcosis with 58 of 
98 patients (59%). With regards to species, 38/52 (73%) of identified isolates were C. neoformans, and 
14/52 (27%) were C. gattii. Notably, 14/14 (100%) of C. gattii isolates were associated with meningitis, as 
compared to only 38/64 (59%) C. neoformans associated with meningitis (Fisher’s exact test: p: 0.003). 
13/14 (93%) were immunocompetent. Overall, C. neoformans is much more common with 82% total isolates 
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Figure 2. Time to diagnosis and missed diagnosis on multiple presentations
Table 1. Patient demographics & clinical variables comparing meningitis & non-meningitis 
cryptococcal infection
Variable All Patients (n (%), IQR) Meningitis (n (%), IQR) Non-meningitis (n (%), IQR) P-value
Total No. of cases 98 58 40 N/A
Age 53 (42-63) 54 (45-63.5) 52 (35.75-63) 0.19°
Gender (Male) 71 (72) 43 (74) 28 (70) 0.65`
Aboriginal & Torres strait Islander 3 (3.1) 3 (5.2) 0 (0) 0.26*
Cryptococcal species
1. C. neoformans 64/78 (82) 38/52 (73) 26/26 (100) 0.003*
2.  C. gattii 14/78 (18) 14/52 (27) 0 0.003*
Comorbidities
1. HIV 9 (9.2) 6 (10.3) 3 (7.5) 0.73*
2.     Diabetes mellitus 22 (22.4) 11 (19) 11(27.5) 0.32`
3.     Liver Disease 10 (10.2) 6 (10) 4 (10) 1.00*
4.     Lung Disease 13 (13.3) 3 (5.2) 10 (25) 0.004`
Presenting symptoms:
1. Fever 30 (31) 22 (38) 8 (21) 0.07` 
2. Headache 49 (50) 39 (67) 10 (25) <0.001`
3. Cough 27 (27.5) 10 (17) 17 (43) 0.005`
4. Vomiting 26 (26.5) 21 (36) 5 (12.8) 0.01`
5.    Altered consciousness 30 (31) 24 (41) 6 (15) 0.007`
6. Diaphoresis 5 (5) 1 (1.7) 4 (10) 0.15*
Clinical findings:
1. Neck stiffness 14 (14.4) 11 (19) 3 (7.7) 0.12`
2. Photophobia 8 (8) 7 (12) 1 (2.5) 0.13*
Delay to diagnosis
1. Time to diagnosis from admission (days) 4 (1 - 8) 4 (1 - 7) 5 (1 - 12.25) 0.32°
2.     Time to diagnosis from symptoms (months) 4 (2 - 8) 4 (2 - 8) 5 (2.75 - 12) 0.14°
3.     Number of presentations 2 (1.25-3) 2 (1.25-3) 3 (1.25-3.75) 0.17°
Biochemical:
1. Lymphopenia 52 (53) 34 (59) 18 (45) 0.18`
2.     Cryptococcal serum titre 128 (32–512) 512 (128-2048) 64 (8-192) <0.001
3.     CSF WBC 23 (1 - 110) 51 (14 - 160) 1 (1 - 1) <0.001°
4.     CSF Protein (mg/L) 625 (422.5 - 1200) 875 (535 - 1475) 375 (267.5 - 530) <0.001°
5.     CSF Glucose (mmol/L) 3.2 (2.2 - 4.3) 2.0 (1.1 – 2.9) 3.5 (2.9 – 4.6) <0.001°
Lumbar puncture opening pressure (cmH2O) 24 (15.5 – 34) 29 (19.5-34.5) 12 (9-15.5) 0.003°
Length of admission (days) 30 (12.75 – 53.5) 44 (26.5 - 72) 9.5 (1.75 - 22.75) <0.001°
*  Fisher Exact test
`  Pearson Chi-square
°Mann-Whitney U test
RESULTS
The introduction of the 2010 IDSA guidelines has altered management and outcomes. Only 9/53 (17%) of all 
patients received standard amphotericin B post 2010 guideline compared with 14/44 (43.2%) prior. 44/53 
(83%) received an alternative formulation (χ2(1) = 8.037, p = 0.005). Notably, 17/23 (74%) of transplant 
infections occurred post-2010. When stratifying for non-transplant patients, 9/36 (25%) patients post-
guideline received standard amphotericin compared to 18/37 (48.6%) of non-transplant patients pre-
guideline (Fisher’s Exact test p = 0.05). Management of transplant patients was not statistically significantly 
altered post-guideline with 1/7 (14.3%) receiving standard Amphotericin B compared with 0/17 post-
guideline (Fisher’s Exact test p = 0.29). Renal treatment complications were not statistically altered with 
guideline introduction (χ2 (1) = 0.09, p = 0.76). There was a significant association between guideline 
implementation and mortality. Only 3/49 (6.1%) deaths due to cryptococcus occurred post 2010 guideline 
as compared with 7/41 (17.1%) (Fisher’s Exact test, p = 0.049). Length of stay has also changed with a 
median of 23 (IQR: 7.5-44) days vs. 36.5 (IQR: 15.5-76.5) prior to guideline introduction (U = 902, z = -1.9, 
p = 0.056).
DISCUSSION
Cryptococcal infection is an important mycosis in both immunocompromised and immunocompetent 
individuals 1,9. This study demonstrates not only a potential for increasing incidence, but also highlights 
the Australian epidemiology of cryptococcal infection with both C. neoformans and C. gattii. 
As might be expected, meningitis patients with positive CSF culture were more severely affected, more 
likely to have positive blood cultures, have a higher serum antigen titre and thus an increased mortality. 
Length of stay was not only greater in the meningitis cohort, but also when stratifying for CSF culture 
positive vs. negative patients. In our cohort the IDSA guidelines appear to be associated with a shorter 
length of stay, decreasing the median admission time by 13 days.
Mortality associated with cryptococcosis has been described between 15-31% 9,11. We report a lower 
cryptococcal attributed mortality of 9.1% over our study period. Death from C. gattii was 7% similar to 
8.7% in British Columbia and lower than 13% previously reported in Australia 14. Since introduction of the 
2010 IDSA guidelines mortality has markedly improved from 17.1% to 6.1%.
Unfortunately a major concern remains the delay to diagnosis of infection Figure 2. Only 25% of patients with 
cryptococcosis are diagnosed on 1st presentation. Our cohort is similar to a smaller report demonstrating 
78% of patients required ≥3 visits to a physician prior to diagnosis 12. 
CONCLUSION
Cryptococcosis remains an important human infection affecting both immunocompetent and 
immunocompromised individuals. Delay in diagnosis remains a significant concern given the association 
with poorer outcomes. The deleterious effects of delay in diagnosis may in part be rectified with utilisation 
of the IDSA management guidelines which have improved mortality and length of stay at our facility.
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